RadNet (RDNT) Q1 2026: Digital Health ARR Surges 95%, Unlocking AI-Driven Margin Expansion
RadNet delivered record Q1 results, propelled by advanced imaging growth and a 95% jump in Digital Health annual recurring revenue (ARR). The company’s AI-powered workflow investments and targeted acquisitions are accelerating both operational throughput and commercial momentum, leading management to raise full-year guidance. With deep health solutions now touching 70% of imaging studies, RadNet is redefining radiology productivity and positioning for sustained margin expansion.
Summary
- AI Integration Accelerates: Deep Health’s platform now supports 70% of imaging studies, reshaping radiology workflow.
- Advanced Imaging Mix Rises: Strategic focus and capital deployment shift procedural volume toward higher-margin modalities.
- Guidance Lifted: Management raised full-year outlook as operational and commercial tailwinds build into Q2.
Business Overview
RadNet is a leading provider of outpatient diagnostic imaging services, operating 440 centers across the U.S. and a growing Digital Health segment. The core business generates revenue through multimodality imaging procedures—MRI, CT, PET-CT, x-ray, ultrasound—while Digital Health monetizes cloud-native AI and informatics solutions via subscription and usage contracts (ARR, annual recurring revenue, is a key metric). RadNet’s business model blends patient volume, payer contracts, and technology-driven workflow improvement, with advanced imaging and digital health as primary growth levers.
Performance Analysis
RadNet posted record Q1 revenue and adjusted EBITDA despite a $13 million revenue drag from severe winter weather. Revenue increased 22.1% year-over-year, with adjusted EBITDA up 36.3%, driving a 115 basis point margin improvement. The advanced imaging mix climbed to 29.3% of procedural volume (up from 26.9% a year ago), reflecting both industry trends and RadNet’s targeted capital investments in MRI and CT equipment. PET-CT procedures surged 35.2% in aggregate, led by demand for prostate cancer and Alzheimer’s diagnostics.
Digital Health delivered 51.5% revenue growth, with ARR reaching $97 million—up 95% YoY—and a robust sales pipeline supporting visibility toward the $140 million year-end target. Recent acquisitions, including Gleamer (AI for x-ray), contributed to segment momentum and cross-sell opportunities. Imaging center adjusted EBITDA margin improved by 188 basis points, and even after normalizing for weather impacts, underlying margin expansion persisted.
- Advanced Imaging Pull-Through: Same-center advanced imaging volumes rose 8.2%, driving disproportionate revenue and profitability gains.
- Acquisitions and De Novo Growth: Two new regional acquisitions and hospital joint ventures added scale, though most EBITDA growth was organic.
- Cash Flow and Working Capital Discipline: Days sales outstanding (DSO) fell to a record 29.5 days, supporting liquidity and future deleveraging.
Operational and financial execution outperformed initial guidance, prompting a $30 million increase to full-year revenue expectations and a $5 million bump to adjusted EBITDA guidance.
Executive Commentary
"Our strategic investments are positioning us to transforming radiology workflow. We are meeting this moment with a sense of urgency because the industry pressures we have discussed previously, radiologist burnouts, massive imaging backlogs, and staffing shortages, and these continue to build."
Case Westorp, President and CEO, Digital Health
"We continue to see and experience a business shift in favor of advanced imaging. The best and most profitable growth we can have comes from same-center performance where we can drive incremental revenue into the same fixed cost base."
Mark Stropper, Executive Vice President and CFO
Strategic Positioning
1. Advanced Imaging Leadership
RadNet’s capital allocation has prioritized advanced imaging modalities, such as MRI and PET-CT, which now generate over 60% of revenue despite representing less than a third of procedural volume. This strategic mix shift leverages higher reimbursement rates and delivers superior margin pull-through, especially as AI-driven workflow improvements expand capacity without proportional cost increases.
2. Digital Health Platform Expansion
Deep Health has transitioned from selling point AI solutions to offering a comprehensive, cloud-native enterprise platform for radiology workflow. The platform orchestrates clinical AI, image management, and reporting, enabling automation and remote operations (TechLive, remote technologist solution). With 70% of studies now processed through AI, productivity gains and T-code reimbursement opportunities are materializing, and a robust ARR pipeline underpins future growth.
3. M&A and Health System Partnerships
RadNet’s acquisition strategy targets regional imaging networks and AI innovators, integrating new assets to expand both the physical footprint and digital capabilities. Recent joint ventures, such as the St. Alphonsus partnership in Idaho, serve as blueprints for embedding Deep Health solutions into hospital ecosystems, broadening the total addressable market and deepening payer and provider relationships.
4. Revenue Cycle Optimization
Improvements in patient collections, real-time insurance eligibility, and proactive communication have driven DSO to industry-leading lows. This working capital discipline fuels organic reinvestment and supports the company’s ability to absorb acquisition-related leverage while maintaining financial flexibility.
5. Regulatory and Reimbursement Readiness
RadNet is actively monitoring CMS reimbursement proposals and accelerating AI deployment in reimbursable modalities (e.g., thyroid and breast ultrasound, CT, MR). The company is well positioned to benefit from new T-code approvals and payer coverage expansion, which will increase the monetization of AI-driven diagnostic enhancements.
Key Considerations
RadNet’s Q1 reflects a business at an inflection point, where technology investments, operational leverage, and commercial execution are converging to drive margin expansion and sustainable growth.
Key Considerations:
- AI-Driven Productivity: Deployment of clinical AI and remote operations is reducing scan times and exam room closures, directly increasing throughput and revenue per center.
- ARR Visibility: Signed but not-yet-live contracts ($7 million ARR) and a $150 million total contract value pipeline provide multi-quarter revenue visibility for Digital Health.
- Integration Discipline: New acquisitions are on or ahead of plan, with early evidence of successful cross-sell and operational synergy realization.
- Margin Expansion Trajectory: Digital Health margins are expected to trough in 2026, with a clear path to 20%+ as recent acquisitions scale and infrastructure investments normalize.
- Balanced Modality Mix: While advanced imaging is the focus, RadNet maintains a multimodality offering to serve both routine and complex diagnostic needs, especially in capitated risk contracts.
Risks
Reimbursement uncertainty remains a structural risk, with CMS’s 2027 fee schedule yet to be published and payer adoption of AI-related T-codes still ramping. Competitive intensity in both outpatient imaging and AI-enabled informatics could pressure pricing or slow adoption. Acquisition integration and execution risk persist, especially as RadNet expands into new geographies and digital product lines. Management’s guidance assumes no major macro or regulatory shocks and continued momentum in both segments.
Forward Outlook
For Q2 2026, RadNet guided to:
- Higher imaging center revenue and adjusted EBITDA, reflecting strong March, April, and early May trends
- Continued Digital Health ARR growth, with $140 million target for year-end ARR reaffirmed
For full-year 2026, management raised guidance:
- Imaging center revenue and adjusted EBITDA ranges increased by $30 million and $5 million, respectively
- Digital Health revenue guidance maintained at $135–$145 million, with adjusted EBITDA of $10–$12 million
Management highlighted several factors that support the outlook:
- Ongoing advanced imaging volume growth and operational leverage
- Robust commercial pipeline and successful integration of recent acquisitions
Takeaways
RadNet’s Q1 signals a step-change in both operational and digital health execution, with AI solutions now deeply embedded in the core business and ARR growth well ahead of industry averages.
- AI Productivity Realized: Tangible scan time reductions and workflow automation are expanding capacity and profitability, not just theoretical benefits.
- Organic Growth Dominates: Two-thirds of EBITDA growth comes from same-center and de novo performance, with acquisitions providing incremental upside.
- Watch for Digital Health Margin Inflection: As infrastructure investments moderate and ARR scales, Digital Health margins are set to expand, a key driver for valuation re-rating in future quarters.
Conclusion
RadNet’s execution in Q1 2026 demonstrates that its AI and advanced imaging strategy is translating into real-world margin and growth gains. With a raised outlook, strong cash flow discipline, and deep health ARR momentum, RadNet is well positioned to capitalize on the digital transformation of radiology.
Industry Read-Through
RadNet’s results reinforce that AI-enabled workflow transformation is no longer optional for imaging providers. The rapid shift toward advanced modalities and the operationalization of clinical AI are setting new benchmarks for productivity, margin, and patient throughput. Competitors without integrated digital health platforms risk falling behind as payers and health systems increasingly demand both cost efficiency and diagnostic quality. For the broader healthcare technology sector, RadNet’s ARR and margin trajectory highlight the importance of recurring revenue models, rapid deployment capability, and regulatory readiness as critical differentiators in the evolving imaging and diagnostics landscape.